Collection of Biological Samples From Patients With Rare Neurological Diseases

Overview

The aim of this project is to improve biological collections of patients presenting rare neurological disorders with known or suspected autoimmune origin. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies.

Full Title of Study: “Prospective Collection of Biological Samples From Patients With Rare Neurological Diseases”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: January 1, 2030

Detailed Description

Neuroimmunology is a rapidly expanding field since major advances have been made in basic immunology and numerous new clinical entities have been identified in the last 10 years. Even if these discoveries have led to major advances in patient's management and treatment, a lot of work needs to be done to improve the diagnosis and prognostic biomarkers. It is widely known that the immune system is implicated in a variety of neurological disorders such as infections, encephalitis or multiple sclerosis. Numerous neurological disorders affecting the central and peripheral nervous system can be attributed to the immune system and need to be recognized as some of them can be cured by appropriate immunotherapy. These neurological disorders include autoimmune encephalitis and paraneoplastic neurological syndromes but also myasthenia, chronic demyelinating inflammatory polyneuropathy and other neuromuscular pathologies. These neurological disorders are characterized by the presence of autoantibodies in the patient's sera or cerebral spinal fluid (CSF). These autoantibodies are generally highly specific and necessary to make the diagnosis. However, in some cases, despite strong clinical arguments for a neuroimmunological disorder, we do not identify autoantibodies, leading to inappropriate treatment and a blind follow-up considering the risk of recurrence or of associated tumor. Furthermore, even if the specific role of some autoantibodies or of immune T cells in some of these pathologies are suspected or already documented, for most of them the exact mechanism is still unknown. We need to explore the sera and CSF of these patients to identify new diagnosis and prognosis biomarker. Moreover, the availability of immune cells isolated from these patients will help us to decipher the pathophysiological mechanisms to create new therapeutic strategies. For this, animal models are already available in Centre Physiopathology Toulouse and in the French reference center in Lyon. As genetic susceptibilities may underlie, at least in part, the variability of the clinical manifestations and of the response to treatment, DNA from patients will be collected and immune genes sequencing will be compared to other control groups, included international database.

Interventions

  • Biological: Blood collection on admission and longitudinally
    • Biological samples will be collected in the normal diagnosis and follow-up process. Only blood will be taken in larger quantity (6 tubes of 7mL).

Arms, Groups and Cohorts

  • patients with rare autoimmune neurological diseases

Clinical Trial Outcome Measures

Primary Measures

  • Building a collection of biological samples and clinical-biological data from patients with rare autoimmune neurological diseases
    • Time Frame: Day 0 and through study completion, an average of 1 year
    • Blood sampling

Secondary Measures

  • Identification of new autoantibodies.
    • Time Frame: Day 0 and through study completion, an average of 1 year
    • ELISA
  • Identification of biomarkers regarding the severity (such as cytokines, axonal damages…) in order to help the therapeutic decisions.
    • Time Frame: Day 0 and through study completion, an average of 1 year
    • Analysis of the phenotypic profiling of blood immune cells by multicolor fluorescence-activated cell sorter (FACS) analysis and of the transcriptomic profiling of blood immune cells by RNA sequencing
  • Exploration of the pathophysiological mechanisms of rare autoimmune neurological pathologies.
    • Time Frame: Day 0 and through study completion, an average of 1 year
    • Knock-out or knock-in animal models for one specific protein will be used to determine in vivo if the pathophysiological mechanisms of rare autoimmune neurological disorder can be induced by the abnormal expression of this protein.

Participating in This Clinical Trial

Inclusion Criteria

  • all patients with neurological disorders, with known or probable autoimmune involvement. This includes adults and children and peripheral and/or central nervous system symptoms. – Social coverage up to date. Exclusion Criteria:

  • Patients with neurological damage from which the autoimmune character can be excluded. – Known anemia and hemoglobin <10 g / dl – Patients under protective supervision (guardianship, curators) – Pregnant or breastfeeding woman

Gender Eligibility: All

Minimum Age: 6 Years

Maximum Age: 99 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Toulouse
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • ChloĆ© Bost, PharmD, PhD, Principal Investigator, University Hospital, Toulouse
  • Overall Contact(s)
    • ChloĆ© Bost, PharmD, PhD, 5 61 77 61 44, bost.c@chu-toulouse.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.